Vanda's PhII data offer hope for gastroparesis patients who have seen no new treatments in decades
As one of the handful of drugs-in-development for gastroparesis, Vanda Pharmaceuticals’ $VNDA tradipitant has set itself apart for the condition that affects about 6 million in the United States and has not seen an approval in nearly four decades. On Monday, the drugmaker released mid-stage data that impressed, showing the drug conferred a statistically significant improvement in nausea symptoms and nausea-free days.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.